VIRALYTICS LIMITED - Announcements

Currently unlisted. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

VLA	Dr. Malcolm McColl commences as Chief Executive Officer	PRICE SENSITIVE	21/01/13	Share
VLA	Phase II Melanoma Study Achieves Interim Efficacy Milestone	PRICE SENSITIVE	13/12/12	Share
VLA	New CAVATAK intravenous cancer study scheduled in UK	PRICE SENSITIVE	10/12/12	Share
VLA	CAVATAK Bladder Cancer Positive Preliminary Data	PRICE SENSITIVE	29/11/12	Share
VLA	Reinstatment to Official Quotation	PRICE SENSITIVE	22/11/12	Share
VLA	Underwritten Share Purchase Plan	PRICE SENSITIVE	22/11/12	Share
VLA	Suspension from Official Quotation	PRICE SENSITIVE	21/11/12	Share
VLA	Trading Halt	PRICE SENSITIVE	19/11/12	Share
VLA	Starpharma VP Dr Malcolm McColl appointed CEO of Viralytics	PRICE SENSITIVE	14/11/12	Share
VLA	Viralytics receives $1.467m R&D tax concession	PRICE SENSITIVE	13/11/12	Share
VLA	CAVATAK Phase I Trial International Conference Presentation	PRICE SENSITIVE	05/11/12	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	24/10/12	Share
VLA	Update - Phase 2 Melanoma Clinical Trial - CAVATAK	PRICE SENSITIVE	22/10/12	Share
VLA	Appendix 4E and Financial Report	PRICE SENSITIVE	31/08/12	Share
VLA	Japanese patent	PRICE SENSITIVE	09/08/12	Share
VLA	US patent	PRICE SENSITIVE	02/08/12	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/12	Share
VLA	Market Update on Viralytics	PRICE SENSITIVE	30/07/12	Share
VLA	Board and Management changes	PRICE SENSITIVE	24/07/12	Share
VLA	First Patient commences USA Phase II CALM Study	PRICE SENSITIVE	09/07/12	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	26/04/12	Share
VLA	China patent - blood cancer	PRICE SENSITIVE	29/03/12	Share
VLA	Appendix 4D and Half Year Report	PRICE SENSITIVE	28/02/12	Share
VLA	Granting of USA patent	PRICE SENSITIVE	15/02/12	Share
VLA	First patients commence treatment in US Phase II trial	PRICE SENSITIVE	19/01/12	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	18/01/12	Share
VLA	Phase II trial - additional cancer center joins trial	PRICE SENSITIVE	09/12/11	Share
VLA	Australian patent	PRICE SENSITIVE	01/12/11	Share
VLA	Underwritten Share Purchase Plan	PRICE SENSITIVE	30/11/11	Share
VLA	Trading Halt	PRICE SENSITIVE	28/11/11	Share
VLA	USA patent Notice of Allowance	PRICE SENSITIVE	25/11/11	Share
VLA	Quarterly Cashflow Report	PRICE SENSITIVE	31/10/11	Share
VLA	US site approval to dose first patient in Phase II trial	PRICE SENSITIVE	20/10/11	Share
VLA	CAVATAK kills cells resistant to approved melanoma drug	PRICE SENSITIVE	26/09/11	Share
VLA	Echo virus Chinese patent granted	PRICE SENSITIVE	01/09/11	Share
VLA	Appendix 4E and statutory accounts	PRICE SENSITIVE	26/08/11	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	26/07/11	Share
VLA	Pre-clinical activity of CAVATAK in pancreatic cancer	PRICE SENSITIVE	07/07/11	Share
VLA	Open Briefing - Update on Phase II Trials for Cavatak	PRICE SENSITIVE	28/06/11	Share
VLA	Allowance of FDA Application CAVATAK Phase II Melanoma Trial	PRICE SENSITIVE	27/06/11	Share
VLA	FDA Investigational New Drug (IND) Application Update	PRICE SENSITIVE	23/05/11	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	19/04/11	Share
VLA	Phase I IV Trial Update	PRICE SENSITIVE	05/04/11	Share
VLA	Appendix 4D and Half-Year Financial Report	PRICE SENSITIVE	28/02/11	Share
VLA	Chinese patent	PRICE SENSITIVE	23/02/11	Share
VLA	Pancreatic cancer research	PRICE SENSITIVE	11/02/11	Share
VLA	Chinese patent	PRICE SENSITIVE	31/01/11	Share
VLA	Oncolytic Virus Portfolio Pre-clinical Research Publication	PRICE SENSITIVE	27/01/11	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	14/01/11	Share
VLA	FDA Investigational New Drug Application - Market Update	PRICE SENSITIVE	02/12/10	Share
VLA	Investigational New Drug Application lodged with the FDA	PRICE SENSITIVE	03/11/10	Share
VLA	Modified Oncolytic virus patent granted	PRICE SENSITIVE	28/10/10	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	08/10/10	Share
VLA	Intravenous trial Melanoma Breast and Prostate update	PRICE SENSITIVE	06/10/10	Share
VLA	Appendix 4E and 2010 Financial Report	PRICE SENSITIVE	31/08/10	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	29/07/10	Share
VLA	Exercise of Listed Options and Placement raises $2.9m	PRICE SENSITIVE	02/07/10	Share
VLA	US FDA pre-IND meeting update	PRICE SENSITIVE	25/06/10	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	07/04/10	Share
VLA	Placement	PRICE SENSITIVE	25/03/10	Share
VLA	Appendix 4D and Half-Year Financial Report	PRICE SENSITIVE	26/02/10	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/10	Share
VLA	Melanoma Phase I Clinical Trial Report Completed	PRICE SENSITIVE	19/01/10	Share
VLA	Australian echovirus family patent granted	PRICE SENSITIVE	07/01/10	Share
VLA	Head and Neck trial dosing increase	PRICE SENSITIVE	18/12/09	Share
VLA	Viralytics Limited - Share Price Movement	PRICE SENSITIVE	19/11/09	Share
VLA	Melanoma, Breast and Prostate cancer IV trial - 2nd site	PRICE SENSITIVE	02/11/09	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/09	Share
VLA	Head and Neck cancer study additional site - Royal Adelaide	PRICE SENSITIVE	29/10/09	Share
VLA	Head and Neck Trial Update	PRICE SENSITIVE	08/10/09	Share
VLA	Melanoma trial completed	PRICE SENSITIVE	22/09/09	Share
VLA	Preliminary Final Report and FY2009 Statutory Accounts	PRICE SENSITIVE	31/08/09	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	29/07/09	Share
VLA	Options Rights Issue Result and Capital Raising Update	PRICE SENSITIVE	01/07/09	Share
VLA	$US6m convertible note facility signed	PRICE SENSITIVE	12/06/09	Share
VLA	Supplementary Prospectus	PRICE SENSITIVE	01/06/09	Share
VLA	Supplementary Prospectus issued and funding offer received	PRICE SENSITIVE	01/06/09	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	29/04/09	Share
VLA	Non-Renounceable Options Rights Issue	PRICE SENSITIVE	22/04/09	Share
VLA	IV breast prostate and melanoma trial dosage increase	PRICE SENSITIVE	20/04/09	Share
VLA	Viralytics strengthens US patent portfolio	PRICE SENSITIVE	30/03/09	Share
VLA	International Conference Presentation	PRICE SENSITIVE	20/03/09	Share
VLA	Placement of shares and Appendix 3B	PRICE SENSITIVE	13/03/09	Share
VLA	Head and Neck cancer trial 1st patient injected	PRICE SENSITIVE	10/02/09	Share
VLA	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/09	Share
VLA	Stomach cancer Evatak publication	PRICE SENSITIVE	19/12/08	Share
VLA	Brain Cancer Update	PRICE SENSITIVE	12/12/08	Share
VLA	Head and Neck clinical trial approved	PRICE SENSITIVE	09/12/08	Share

VLADr. Malcolm McColl commences as Chief Executive Officer
21/01/13	PRICE SENSITIVE	Share
VLAPhase II Melanoma Study Achieves Interim Efficacy Milestone
13/12/12	PRICE SENSITIVE	Share
VLANew CAVATAK intravenous cancer study scheduled in UK
10/12/12	PRICE SENSITIVE	Share
VLACAVATAK Bladder Cancer Positive Preliminary Data
29/11/12	PRICE SENSITIVE	Share
VLAReinstatment to Official Quotation
22/11/12	PRICE SENSITIVE	Share
VLAUnderwritten Share Purchase Plan
22/11/12	PRICE SENSITIVE	Share
VLASuspension from Official Quotation
21/11/12	PRICE SENSITIVE	Share
VLATrading Halt
19/11/12	PRICE SENSITIVE	Share
VLAStarpharma VP Dr Malcolm McColl appointed CEO of Viralytics
14/11/12	PRICE SENSITIVE	Share
VLAViralytics receives $1.467m R&D tax concession
13/11/12	PRICE SENSITIVE	Share
VLACAVATAK Phase I Trial International Conference Presentation
05/11/12	PRICE SENSITIVE	Share
VLAAppendix 4C - quarterly
24/10/12	PRICE SENSITIVE	Share
VLAUpdate - Phase 2 Melanoma Clinical Trial - CAVATAK
22/10/12	PRICE SENSITIVE	Share
VLAAppendix 4E and Financial Report
31/08/12	PRICE SENSITIVE	Share
VLAJapanese patent
09/08/12	PRICE SENSITIVE	Share
VLAUS patent
02/08/12	PRICE SENSITIVE	Share
VLAAppendix 4C - quarterly
31/07/12	PRICE SENSITIVE	Share
VLAMarket Update on Viralytics
30/07/12	PRICE SENSITIVE	Share
VLABoard and Management changes
24/07/12	PRICE SENSITIVE	Share
VLAFirst Patient commences USA Phase II CALM Study
09/07/12	PRICE SENSITIVE	Share
VLAAppendix 4C - quarterly
26/04/12	PRICE SENSITIVE	Share
VLAChina patent - blood cancer
29/03/12	PRICE SENSITIVE	Share
VLAAppendix 4D and Half Year Report
28/02/12	PRICE SENSITIVE	Share
VLAGranting of USA patent
15/02/12	PRICE SENSITIVE	Share
VLAFirst patients commence treatment in US Phase II trial
19/01/12	PRICE SENSITIVE	Share
VLAAppendix 4C - quarterly
18/01/12	PRICE SENSITIVE	Share
VLAPhase II trial - additional cancer center joins trial
09/12/11	PRICE SENSITIVE	Share
VLAAustralian patent
01/12/11	PRICE SENSITIVE	Share
VLAUnderwritten Share Purchase Plan
30/11/11	PRICE SENSITIVE	Share
VLATrading Halt
28/11/11	PRICE SENSITIVE	Share
VLAUSA patent Notice of Allowance
25/11/11	PRICE SENSITIVE	Share
VLAQuarterly Cashflow Report
31/10/11	PRICE SENSITIVE	Share
VLAUS site approval to dose first patient in Phase II trial
20/10/11	PRICE SENSITIVE	Share
VLACAVATAK kills cells resistant to approved melanoma drug
26/09/11	PRICE SENSITIVE	Share
VLAEcho virus Chinese patent granted
01/09/11	PRICE SENSITIVE	Share
VLAAppendix 4E and statutory accounts
26/08/11	PRICE SENSITIVE	Share
VLAAppendix 4C - quarterly
26/07/11	PRICE SENSITIVE	Share
VLAPre-clinical activity of CAVATAK in pancreatic cancer
07/07/11	PRICE SENSITIVE	Share
VLAOpen Briefing - Update on Phase II Trials for Cavatak
28/06/11	PRICE SENSITIVE	Share
VLAAllowance of FDA Application CAVATAK Phase II Melanoma Trial
27/06/11	PRICE SENSITIVE	Share
VLAFDA Investigational New Drug (IND) Application Update
23/05/11	PRICE SENSITIVE	Share
VLAAppendix 4C - quarterly
19/04/11	PRICE SENSITIVE	Share
VLAPhase I IV Trial Update
05/04/11	PRICE SENSITIVE	Share
VLAAppendix 4D and Half-Year Financial Report
28/02/11	PRICE SENSITIVE	Share
VLAChinese patent
23/02/11	PRICE SENSITIVE	Share
VLAPancreatic cancer research
11/02/11	PRICE SENSITIVE	Share
VLAChinese patent
31/01/11	PRICE SENSITIVE	Share
VLAOncolytic Virus Portfolio Pre-clinical Research Publication
27/01/11	PRICE SENSITIVE	Share
VLAAppendix 4C - quarterly
14/01/11	PRICE SENSITIVE	Share
VLAFDA Investigational New Drug Application - Market Update
02/12/10	PRICE SENSITIVE	Share
VLAInvestigational New Drug Application lodged with the FDA
03/11/10	PRICE SENSITIVE	Share
VLAModified Oncolytic virus patent granted
28/10/10	PRICE SENSITIVE	Share
VLAAppendix 4C - quarterly
08/10/10	PRICE SENSITIVE	Share
VLAIntravenous trial Melanoma Breast and Prostate update
06/10/10	PRICE SENSITIVE	Share
VLAAppendix 4E and 2010 Financial Report
31/08/10	PRICE SENSITIVE	Share
VLAAppendix 4C - quarterly
29/07/10	PRICE SENSITIVE	Share
VLAExercise of Listed Options and Placement raises $2.9m
02/07/10	PRICE SENSITIVE	Share
VLAUS FDA pre-IND meeting update
25/06/10	PRICE SENSITIVE	Share
VLAAppendix 4C - quarterly
07/04/10	PRICE SENSITIVE	Share
VLAPlacement
25/03/10	PRICE SENSITIVE	Share
VLAAppendix 4D and Half-Year Financial Report
26/02/10	PRICE SENSITIVE	Share
VLAAppendix 4C - quarterly
29/01/10	PRICE SENSITIVE	Share
VLAMelanoma Phase I Clinical Trial Report Completed
19/01/10	PRICE SENSITIVE	Share
VLAAustralian echovirus family patent granted
07/01/10	PRICE SENSITIVE	Share
VLAHead and Neck trial dosing increase
18/12/09	PRICE SENSITIVE	Share
VLAViralytics Limited - Share Price Movement
19/11/09	PRICE SENSITIVE	Share
VLAMelanoma, Breast and Prostate cancer IV trial - 2nd site
02/11/09	PRICE SENSITIVE	Share
VLAAppendix 4C - quarterly
30/10/09	PRICE SENSITIVE	Share
VLAHead and Neck cancer study additional site - Royal Adelaide
29/10/09	PRICE SENSITIVE	Share
VLAHead and Neck Trial Update
08/10/09	PRICE SENSITIVE	Share
VLAMelanoma trial completed
22/09/09	PRICE SENSITIVE	Share
VLAPreliminary Final Report and FY2009 Statutory Accounts
31/08/09	PRICE SENSITIVE	Share
VLAAppendix 4C - quarterly
29/07/09	PRICE SENSITIVE	Share
VLAOptions Rights Issue Result and Capital Raising Update
01/07/09	PRICE SENSITIVE	Share
VLA$US6m convertible note facility signed
12/06/09	PRICE SENSITIVE	Share
VLASupplementary Prospectus
01/06/09	PRICE SENSITIVE	Share
VLASupplementary Prospectus issued and funding offer received
01/06/09	PRICE SENSITIVE	Share
VLAAppendix 4C - quarterly
29/04/09	PRICE SENSITIVE	Share
VLANon-Renounceable Options Rights Issue
22/04/09	PRICE SENSITIVE	Share
VLAIV breast prostate and melanoma trial dosage increase
20/04/09	PRICE SENSITIVE	Share
VLAViralytics strengthens US patent portfolio
30/03/09	PRICE SENSITIVE	Share
VLAInternational Conference Presentation
20/03/09	PRICE SENSITIVE	Share
VLAPlacement of shares and Appendix 3B
13/03/09	PRICE SENSITIVE	Share
VLAHead and Neck cancer trial 1st patient injected
10/02/09	PRICE SENSITIVE	Share
VLAAppendix 4C - quarterly
30/01/09	PRICE SENSITIVE	Share
VLAStomach cancer Evatak publication
19/12/08	PRICE SENSITIVE	Share
VLABrain Cancer Update
12/12/08	PRICE SENSITIVE	Share
VLAHead and Neck clinical trial approved
09/12/08	PRICE SENSITIVE	Share

REFRESH

First

VIRALYTICS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Top Stories

Corporate Spotlight
Not Yet Available